Conference Agenda
Day One (Thursday, 24th January 2008)
09:00 Registration and refreshments
09:30 Opening address from the chair
INTELLECTUAL PROPERTY & REGULATORY ISSUES
09:40 Patenting antibodies - IP issues
• Learn how to protect antibodies through patenting IP landscape for antibody phage display
• Comparison of USPTO and EPO approaches to antibody claims
• Strategies for protecting antibodies
• Approaches for assessing third party antibody patents
Dr Philip Webber, European Patent Attorney, Frank B Dehn
10.20 Target-specific recombinant human antibodies: An erythropoietic mimic human antibody as an
example
• Generation of ABT007
• in vitro potency
• in vivo potency
• Structural analysis to identify a novel binding site
• Critical success factors
Dr Ed Reilly, Project Leader, Therapeutic Abs GPRD Cancer Discovery, Abbott Laboratories
11:00 Morning refreshments
NOVEL TECHNOLOGIES IN ANTIBODY DISCOVERY
11:20 Screening antibodies like small molecules
• Points to consider for antibody sample preparation
• Assay formats and success factors
• Comparing and contrasting the approaches taken for screening for functional leads and for
improved variants
• Enhanced throughput and its impact on your therapeutic antibody discovery portfolio
Dr Tristan Vaughan, Director, Discovery, Respiratory & Inflammation, Cambridge Antibody
Technology
12:00 Discovery of antibody biopharmaceuticals
• Characteristics of therapeutic antibodies
• Variable region discovery
• Value of research reagents
• Technology development
Dr Alastair Lawson, Director of Antibody Biology, UCB-Celltech
12:30 Title to be announced
Dr David Estell, Vice President of Technology, Genencor
13:10 Networking lunch
TEGENERO AND THE DUFF REPORT
14:10 New phase I recommendations
Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics
RECOMBINANT POLYCLONAL ANTIBODIES
14:50 Recombinant polyclonal antibodies
• Cloning of better antibodies faster using human donor blood
• Expression of consistent batches of polyclonal antibody compositions
• Effi cacy & synergy achieved with Recombinant Polyclonal Antibodies
• Safety issues for Recombinant Polyclonal Antibodies
Dr Kirsten Drejer, Chief Executive Officer, Symphogen
15:30 Afternoon refreshments
15:50 Developing recombinant polyclonal antibody therapeutics
• Rational for developing polyclonal antibody therapeutics
• Identifi cation of polyclonal antibody leads using the SymplexTM platform
• Manufacturing polyclonal antibodies using the SympressTM platform
• CMC and regulatory challenges in developing polyclonal antibody therapeutics
Dr Søren Bregenholt, Vice President of Project Management, Symphogen
SYNTHETIC THERAPEUTIC ANTIBODIES
16:30 Developing therapeutic human antibody leads using phage display technology
• Dyax Fab phage and phagemid libraries
• Unique combination natural antibody diversity from human donors (light chains and HCDR3) and
synthetic diversity in key VH antigen contact sites
• High affi nity leads without affi nity maturation
• Discovery and characterization of potent and selective protease inhibitor antibody leads
Mr Rene Hoet, Vice President Discovery Research, Dyax
17:20 Closing remarks from the chair
Dr Alastair Lawson, Director of Antibody Biology , UCB-Celltech
17:25 Networking Drinks Reception - Take your discussions further and build new relationships
in a relaxed and informal setting .
Day Two (Friday, 25th January 2008)
09:00 Registration and refreshments
09:30 Opening address
ANTIBODY ENGINEERING
9:40 Therapeutics based on
single variable domains: translating advantages of the
Nanobody platform
into novel protein drugs
• What are the shortcomings of conventional antibodies?
• How can Nanobodies overcome these?
• What type of protein drugs can be made with this platform?
Dr Hennie Hoogenboom, Chief Scientific Officer, Ablynx
10:20 Functional differences in classes of TNF antagonists - Two classes of biologic agents that
target TNF alpha
• Soluble TNF receptor (Etanercept) and anti-TNF monoclonal antibodies
• All of these agents bear Fc region of IgG1, which has potential to elicit effector functions
• TNF antagonists bind soluble and membrane-bound TNF and to mediate cell killing
• TNF antagonists exhibited functional differences in in-vitro models
Dr Zehra Kaymakcalan, Sr. Principle Scientist, Biologics, Abbott Bioresearch
11:00 Morning refreshments
11:20 Rapid monoclonal antibody analysis by Label-Free Capillary Gel Electrophoresis (CGE) and
Capillary Zone
Electrophoresis (CZE) using deltaDOT's Peregrine system
• Work faster: Increase throughput in antibody analysis (reduced antibody analysis in 18 minutes;
whole antibody analysis in 8 mins)
• Work smarter: Obtain extra information on the state of the antibody, often in a single experiment
• Work better: Achieve better resolution and sensitivity, excellent quantifi cation, dynamic range and
linearity
Dr Stuart Hassard, Head of Biology, deltaDOT
IMMUNOGENICITY
12:00 Do we need to
differentiate binding and neutralizing antibodies?
Dr Arno Kromminga , Institute for Immunology, Pathology and Molecular Biology ,
IPM-Biotech
12:30 Immunogenicity: Screening in a global context
• Immunogenicity risk assessment and regulatory guidelines
• Strategies for Immunogenicity identifi cation and testing
• Addressing the challenges of antibody immunogenicity
• Selected case studies on antibody therapeutics
Mr Philippe Stas, Chief Operating Officer, AlgoNomics
12:40 Networking lunch
TREATMENTS FOR DISEASES
14:00 Therapeutic
monoclonal antibodies in rheumatic diseases: rationale and
mechanisms of action
• Therapeutic monoclonal antibodies have emerged as a major force in the
immunotherapy of several rheumatic diseases
• The first generation therapeutic monoclonal antibodies against cell surface
molecules or soluble factors have proven effective in many rheumatic diseases
• The mechanisms of action of therapeutic monoclonal antibodies include cytolysis of target cells,
induction of apoptosis of target cells, blockade of co-stimulatory molecules, and/or neutralization of
soluble factors and their receptors
Professor Jagadeesh Bayry, Scientist, Centre de Recherche des Cordeliers
14:40 Human monoclonal antibodies as anti-infective drugs
• Concept of antibodies in infectious diseases
• Anti-infective mAb products in clinical development
• Strategies for design of anti-infective mAb products
Dr Jan ter Meulen, Executive Director Infectious Diseases, Crucell
15:20 Generation of therapeutic antibodies for onclogy using transgenic mouse and display
technologies
• Therapeutic oncology antibodies from the humanised mouse
- review and case studies
• Advantages/disadvantages of the mouse and display platforms
• Combining humanise mouse and display platforms
Dr David Blakey, Senior Principal Scientist/Project Director, Cancer Discovery, AstraZeneca
16:00 Afternoon refreshments
LOOKING AHEAD - DEVELOPING NEXT GENERATION OF ANTIBODIES
16:20 Dual-targeting antibody approaches for cancer therapy
• Challenges faced with classical antibodies
• Modularity of human domain antibodies
• Approaches for the development of dual-targeting antibodies
• Application to cancer targets
• In vitro and in vivo PoC
Dr Michael Steward, Manager, Biopharm CEDD, Domantis
17:00 BiTE antibodies recruit cytotoxic T cells for cancer therapy
• What makes BiTE antibodies different from conventional antibodies
• In-vivo proof of concept for four distinct BiTE antibodies
• Features of anti-EpCAM BiTE antibody MT110
• Clinical proof of concept with anti-CD19 BiTE MT103/MEDI-538
• Update from clinical development of MT103/MEDI-538
Professor Patrick Baeuerle, Chief Scientific Officer, Micromet
17:10 Chair's closing remarks
Dr Alastair Lawson, Director of Antibody Biology, UCB-Celltech
17:20 End of conference
- PRICING -
- 2 day Conference ticket - available for only GBP £1299
- If you would like to send more than 1 person then take advantage of the 3 for 2 offer.
Send 3 people but only pay for 2.
Excellent networking opportunities.
-BOOKING YOUR PLACEOrdering is simple! All you need to do to book your place is contact Jacob. You can either
call me on TEL: +44 (0)207 549 9971 or email
pharma.conferences1@visiongaingroup.com